Apr 4, 2025
Trials from the 2025 American College of Cardiology scientific
sessions, including the WARRIOR, PROTECT TAVI, DAPATAVI, and SOUL
are reviewed by John Mandrola, MD
This podcast is intended for healthcare professionals
only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Thank you Comments
II WARRIOR Women’s IschemiA TRial to Reduce Events
In Non-ObstRuctive CAD
- Keep Fighting INOCA After Neutral WARRIOR Trial
https://www.medscape.com/viewarticle/keep-fighting-inoca-after-neutral-warrior-trial-2025a10007uf
III Cerebral Embolic Protection in TAVI
- PROTECT TAVI
https://www.nejm.org/doi/full/10.1056/NEJMoa2415120
- PROTECTED TAVR
https://www.nejm.org/doi/full/10.1056/NEJMoa2204961
- Instrumental Variables in Randomized Trials
https://evidence.nejm.org/doi/10.1056/EVIDctw2400204
IV DAPATAVI
- SGLT2 Inhibitors Progressing to New Standard After TAVI
https://www.medscape.com/viewarticle/sglt2-inhibitors-progressing-new-standard-after-tavi-2025a100081y
- Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve
Implantation
https://www.nejm.org/doi/full/10.1056/NEJMoa2500366
V SOUL Study of Oral Semaglutide and CV outcomes in
Diabetes
- Oral GLP-1 Receptor Agonist Reduces CV Risk
https://www.medscape.com/viewarticle/oral-glp-1-receptor-antagonist-reduces-cv-risk-2025a10007kr
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk
Type 2 Diabetes
https://www.nejm.org/doi/full/10.1056/NEJMoa2501006
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean
of Weill Cornell Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net